Crystal structure of SmTPI and TsTPI showing their cysteine residues. by Pedro Jimenez-Sandoval (831603)

Osteoclast differentiation. by Bo Huang (30906)

Cell migration assay. by Bo Huang (30906)

“…The white triangles indicate the cells that migrated from the upper chamber to the lower chamber (Fig. 4A). A: 0Gy + 0ng/ml Sema3a; B: 0Gy + 50ng/ml Sema3a; C: 2Gy + 0ng/ml Sema3a; D: 2Gy + 50ng/ml Sema3a (N = 5). …”

Gliding motility of the size-modified HMW2-derivative mutants. by Daisuke Nakane (833480)

HDAC inhibitors block the proliferative rate of radial glia cells. by Yi Tao (178829)

“…<p>(A). Representative co-staining images showing the BrdU- and BLBP-positive cells in control (A1–A3), TSA-treated (50 nM, A4–A6) and VPA-treated (1 mM, A7–A9) tecta. …”

Table1_Loss-of-function N178T variant of the human P2Y4 receptor is associated with decreased severity of coronary artery disease and improved glucose homeostasis.DOCX by Michael Horckmans (14206388)

“…The relevance of these data has, however, not been explored to date in humans. In a population study comprising 50 patients with coronary artery disease (CAD) and 50 age-matched control individuals, we analyzed P2RY4 mutations and their potential association with CAD severity and fasting plasma parameters. …”

Temperature monitoring and viral shedding following BA.1 and VIC01 challenge and rechallenge. by Kathryn A. Ryan (13730701)

DataSheet3_Rhubarb Enema Decreases Circulating Trimethylamine N-Oxide Level and Improves Renal Fibrosis Accompanied With Gut Microbiota Change in Chronic Kidney Disease Rats.PDF by Chunlan Ji (5712218)

DataSheet4_Rhubarb Enema Decreases Circulating Trimethylamine N-Oxide Level and Improves Renal Fibrosis Accompanied With Gut Microbiota Change in Chronic Kidney Disease Rats.docx by Chunlan Ji (5712218)

DataSheet2_Rhubarb Enema Decreases Circulating Trimethylamine N-Oxide Level and Improves Renal Fibrosis Accompanied With Gut Microbiota Change in Chronic Kidney Disease Rats.PDF by Chunlan Ji (5712218)

DataSheet1_Rhubarb Enema Decreases Circulating Trimethylamine N-Oxide Level and Improves Renal Fibrosis Accompanied With Gut Microbiota Change in Chronic Kidney Disease Rats.PDF by Chunlan Ji (5712218)

Cytokine production, degranulation, and functional avidity, of CD62Lhi memory are not influenced by time. by Matthew D. Martin (803107)

The titers of EV-A71 and FMDV in the WT mice. by Huisheng Liu (408091)

Cell apoptosis assay. by Bo Huang (30906)

House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal and Asthmatic Neutrophils via Toll-Like Receptor 4 by Do Hyung Kim (739231)

Bone resorption. by Bo Huang (30906)

“…<p>3A shows the results of the bone resorption assay: Raw264.7 cells plated on bovine cortical bone slices were differentiated into osteoclasts by the addition of 50ng/ml of Rankl and 20ng/ml of M-CSF in the presence or absence of 50ng/ml Sema3a and/or 2Gy radiation. …”

<i>Cited1</i> deficiency increases enterocyte proliferation and decreased cell migration in <i>AhCre⁺Apc^fl/fl</i> mice. by Valérie Méniel (440547)

Discovery of the Diphenyl 6‑Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the... by Jing Liao (193197)

“…The optimal compound <b>J27</b> decreased the release of TNF-α and IL-6 in mouse and human cells J774A.1 and THP-1 (IL-6 IC₅₀ = 0.22 μM) through the NF-κB/MAPK pathway. …”

Discovery of the Diphenyl 6‑Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the... by Jing Liao (193197)

“…The optimal compound <b>J27</b> decreased the release of TNF-α and IL-6 in mouse and human cells J774A.1 and THP-1 (IL-6 IC₅₀ = 0.22 μM) through the NF-κB/MAPK pathway. …”

DataSheet_1_Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basili... by Cong Cheng (2140318)

“…Hence, it was helpful to decrease steroid to the 50% of initial dose ≤ 5 days and to the low-dose steroid ≤ 12 days after basiliximab treatment for intestinal SR-aGVHD patients, which may also be the reasonable steroid decrease protocol for these patients.…”